The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
Other Name: LY2835219
Inclusion Criteria: - Patients with hormone receptor positive metastatic breast cancer for whom there is reasonable expectation that abemaciclib may provide clinical benefit and who are suitable to receive abemaciclib.
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or